Global Health

Why is Global Health Ltd falling/rising?

As of 28-Aug, Global Health Ltd's stock is experiencing a decline of 2.78% after two days of gains, underperforming its sector by 3.25%. Despite this short-term drop, the stock has a year-to-date increase of 23.99% and strong fundamentals, indicating potential for future recovery.

As of 28-Aug, Global Health Ltd's stock price is currently falling, with a change of -42.1, representing a decrease of 2.78%. This decline follows a trend reversal after two consecutive days of gains. The stock has underperformed its sector by 3.25% today and reached an intraday low of Rs 1463.1, which is a drop of 3.27%. <BR><BR>Despite this short-term decline, the stock has shown positive performance over longer periods, with a year-to-date increase of 23.99% and a three-year growth of 107.26%. It is also noteworthy that the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally positive trend prior to this drop. <BR><BR>Additionally, there has been a significant increase in investor participation, with delivery volume rising by 274.98% compared to the 5-day average, suggesting strong interest in the stock despite the current price decrease. The company remains net-debt free and has high institutional holdings, which have increased by 1.44% over the previous quarter, indicating confidence from larger investors. <BR><BR>Overall, while the stock is experiencing a decline at this moment, its strong fundamentals and historical performance suggest potential for recovery in the future.

Which are the latest news on Global Health?

Who are in the management team of Global Health?

The management team of Global Health includes Naresh Kumar Trehan (Chairman & Managing Director), Pankaj Prakash Sahni (Group CEO), and several independent and non-executive directors, such as Hari S Bhartia and Vikram Singh Mehta, who collectively guide the company's strategic direction and governance.

The management team of Global Health includes the following key individuals:<BR><BR>1. **Naresh Kumar Trehan** - Chairman & Managing Director<BR>2. **Pankaj Prakash Sahni** - Group CEO & Whole-Time Director<BR>3. **Hari S Bhartia** - Independent Non-Executive Director<BR>4. **Praveen Mahajan** - Independent Non-Executive Director<BR>5. **Rajan Bharti Mittal** - Independent Non-Executive Director<BR>6. **Ravi Gupta** - Independent Non-Executive Director<BR>7. **Ravi Kant Jaipuria** - Non-Executive Director (Nominated)<BR>8. **Sunil Sachdeva** - Non-Executive Director<BR>9. **Venkatesh Ratnasami** - Non-Executive Director (Nominated)<BR>10. **Vikram Singh Mehta** - Independent Non-Executive Director<BR><BR>This team plays a crucial role in guiding the strategic direction and governance of the company.

What does Global Health do?

Global Health Ltd provides healthcare services in the hospital industry and operates in the small-cap market segment. As of June 2026, it reported net sales of 1,304 Cr and a net profit of 159 Cr, with a market cap of INR 38,207 Cr.

Overview: <BR>Global Health Ltd is engaged in providing healthcare services within the hospital industry and operates in the small-cap market segment.<BR><BR>History: <BR>Global Health Limited was incorporated as 'Global Health Private Limited' in 2004. The company transitioned to a public limited status and changed its name to 'Global Health Limited' on August 11, 2021. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 1,304 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 159 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 38,207 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 66.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.04% <BR>Debt-Equity: -0.07 <BR>Return on Equity: 15.83% <BR>Price to Book: 10.09 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Global Health?

Global Health's peers include Apollo Hospitals, Max Healthcare, Aster DM Quality, Fortis Health, Narayana Hrudaya, Krishna Institute, Dr Agarwal's Health, and Rainbow Child. In terms of management risk, Global Health is rated as good, with a 1-year return of 4.06%, lower than Aster DM Quality's 34.49% but higher than Max Healthcare's -20.39%.

Peers: The peers of Global Health are Apollo Hospitals, Max Healthcare, Aster DM Quality, Fortis Health, Narayana Hrudaya, Krishna Institute, Dr Agarwal's Health, and Rainbow Child.<BR><BR>Quality Snapshot: Excellent management risk is observed at Apollo Hospitals, Narayana Hrudaya, and Rainbow Child, while Good management risk is found at Global Health, Aster DM Quality, Krishna Institute, and the rest. Excellent growth is noted at Apollo Hospitals and Narayana Hrudaya, while Average growth is seen at Global Health, Fortis Health, and the rest. Average capital structure is present at Aster DM Quality and the rest, while Excellent capital structure is attributed to Global Health.<BR><BR>Return Snapshot: Aster DM Quality has the highest 1-year return at 34.49%, while Max Healthcare has the lowest at -20.39%. Global Health's 1-year return is 4.06%, which is higher than Max Healthcare's but lower than Aster DM Quality's. Additionally, Max Healthcare and Narayana Hrudaya have negative six-month returns.

How big is Global Health?

As of 14th August, Global Health Ltd has a market capitalization of 38,233.57 Cr, with recent net sales of 4,683.41 Cr and a net profit of 556.18 Cr over the last four quarters.

As of 14th August, <BR><BR>Market Cap: Global Health Ltd has a market capitalization of 38,233.57 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 4,683.41 Cr, while the sum of Net Profit for the same period is 556.18 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 3,386.41 Cr, and Total Assets amount to 4,733.21 Cr.

Are Global Health Ltd latest results good or bad?

Global Health Ltd's latest results show strong revenue growth of 26.50% year-on-year, reaching ₹1,304.05 crores, but net profit declined slightly by 0.18%, and operating margins contracted, raising concerns about profitability and high valuation. Overall, while revenue growth is positive, the challenges in profit margins suggest a cautious outlook for investors.

Global Health Ltd's latest results present a mixed picture. On one hand, the company achieved a significant revenue growth of 26.50% year-on-year, reaching ₹1,304.05 crores, which is its strongest quarterly performance to date. This reflects successful capacity additions and improved patient footfall across its hospital network.<BR><BR>However, the net profit for the quarter was ₹158.73 crores, which represents a slight decline of 0.18% year-on-year, despite the substantial revenue increase. Additionally, the operating margin has contracted from 23.92% to 21.99%, and the PAT margin has dropped from 15.42% to 12.06%. These declines indicate that while the company is expanding its top line, it is struggling to translate that growth into proportional profit, primarily due to rising employee costs and increased interest expenses.<BR><BR>The company's premium valuation, trading at a P/E multiple of 66x, raises concerns about whether the current growth trajectory can sustain investor confidence, especially in light of the margin compression and flat profit growth. Overall, while the revenue growth is a positive sign, the challenges in profitability and high valuation suggest a cautious outlook for investors.

Should I buy, sell or hold Global Health Ltd?

When is the next results date for Global Health Ltd?

The next results date for Global Health Ltd is 30 July 2026.

The next results date for Global Health Ltd is on 30 July 2026.

Is Global Health technically bullish or bearish?

As of December 4, 2025, the market trend is mildly bearish, with bearish signals from the weekly MACD and Bollinger Bands, despite some mixed bullish indicators, suggesting caution in the current environment.

As of 4 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and Bollinger Bands indicating bearish conditions. The monthly MACD is also mildly bearish, while the daily moving averages show a mildly bullish signal, creating a mixed picture. The KST is bullish on a weekly basis, but the overall trend is influenced by the mildly bearish OBV readings. The Dow Theory reflects a mildly bullish stance on the weekly chart, but with no trend on the monthly. Overall, the bearish indicators outweigh the bullish signals, suggesting caution in the current market environment.

How has been the historical performance of Global Health?

Global Health has shown strong financial growth over the past five years, with net sales increasing from INR 1,446.74 crore in March 2021 to INR 3,692.32 crore in March 2025, alongside significant rises in operating profit and profits before and after tax. Despite challenges in cash flow management, the company has expanded its asset base significantly during this period.

Answer:<BR>The historical performance of Global Health shows a consistent upward trend in key financial metrics over the past five years.<BR><BR>Breakdown:<BR>Global Health's net sales have increased significantly from INR 1,446.74 crore in March 2021 to INR 3,692.32 crore in March 2025, reflecting a strong growth trajectory. Total operating income followed a similar pattern, rising from INR 1,446.74 crore in March 2021 to INR 3,692.32 crore in March 2025. The company's operating profit (PBDIT) also saw substantial growth, climbing from INR 222.85 crore in March 2021 to INR 956.17 crore in March 2025. Profit before tax increased from INR 32.46 crore in March 2021 to INR 647.26 crore in March 2025, while profit after tax rose from INR 28.81 crore to INR 481.32 crore during the same period. The earnings per share (EPS) showed fluctuations, peaking at INR 60.79 in March 2023 before settling at INR 17.92 in March 2025. On the balance sheet, total assets grew from INR 2,666.29 crore in March 2021 to INR 4,733.21 crore in March 2025, while total liabilities increased from INR 2,668.36 crore to INR 4,733.21 crore. The cash flow from operating activities improved from INR 241 crore in March 2021 to INR 623 crore in March 2025, although the net cash flow showed a decline, ending at INR -194 crore in March 2025 compared to INR -78 crore in March 2021. Overall, Global Health has demonstrated robust growth in revenue and profitability, alongside an expanding asset base, despite some challenges in cash flow management.

Is Global Health overvalued or undervalued?

As of November 19, 2025, Global Health is considered very expensive with a PE ratio of 53.76 and high valuation ratios compared to peers, despite a strong three-year return of 189.89%, indicating it is overvalued in the current market.

As of 19 November 2025, the valuation grade for Global Health has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently deemed overvalued. Key ratios highlight this assessment, with a PE ratio of 53.76, a Price to Book Value of 8.70, and an EV to EBITDA of 33.44, all of which are considerably high compared to industry norms.<BR><BR>In comparison to its peers, Global Health's valuation stands out, particularly when looking at Max Healthcare with a PE of 80.06 and Apollo Hospitals at 64.09. This suggests that while Global Health is indeed very expensive, it is relatively more attractive than some of its peers. Notably, the company has shown a strong return of 189.89% over the past three years, outperforming the Sensex's 38.15% return during the same period, which may contribute to its elevated valuation despite the current market conditions.

Who are the top shareholders of the Global Health?

The top shareholders of Global Health include Naresh Trehan with 33.03%, Dunearn Investments (Mauritius) Pte Ltd at 14.86%, 25 mutual fund schemes holding 10.36%, and 158 Foreign Institutional Investors (FIIs) with a combined 11.76%. Individual investors account for 6.53% of the shareholding.

The top shareholders of Global Health include Naresh Trehan, who is the promoter with the highest holding at 33.03%. The highest public shareholder is Dunearn Investments (Mauritius) Pte Ltd, holding 14.86%. Additionally, the company has 25 mutual fund schemes collectively holding 10.36%, and 158 Foreign Institutional Investors (FIIs) with a combined holding of 11.76%. Individual investors account for 6.53% of the shareholding.

Has Global Health declared dividend?

No Dividend History Available